9/28/2010
1
Pharmacodynamics in practice
Eric Nuermberger, MD
Center for TB ResearchJohns Hopkins University
September 23, 2010
A caseCC/HPI: 61 yo F with new dx of sm+ pulmonary TB
Past medical hx: obese (110 kg) ; poorly controlled DM; HIV negative
Rx: predominantly twice-weekly, DOT, standard “maximum” doses
Response: still Cx+ at 4 mo.
TDM: INH 8.84 μg/ml (goal = 9 -15)RIF 5.85 μg/ml (goal = 8 -24)
Intervention: restart 4-drug therapy with INH 400 mg, RIF 900 mg
Outcome: cured with an additional 6 months of daily therapy
Diagnosis: Pulmonary tuberculosis with
sub-therapeutic rifampin exposure resulting in treatment failureresulting in treatment failure
9/28/2010
2
Dose-response curve for a TB drugef
fect
Sub-therapeutic
Clinical failure probable
Resistance to i d
Sub-optimal
Long
ExposureExposure
Ant
i-TB
e companion drug possible
Long treatment duration
Failure or relapse possible
Optimal
Short treatment duration
Clinical failure
improbable
Susceptibility testing
• Critical concentration: the drug concentration “breakpoint” which defines whether a bacterial isolate is susceptible or resistant – if bacteria grow, they are considered “resistant”– if not, they are considered “susceptible”
• Minimum inhibitory concentration (MIC): the lowest drug conc. to prevent growth
• Minimum bactericidal concentration (MBC): the lowest drug conc. to kill ≥99% of bacteria
Drug susceptibility is not uniform and resistance is not absolute
Susceptibility to rifampin Susceptibility to streptomycin
Jureen et al, J. Clin Micro (2010)
9/28/2010
3
Pharmacokinetics (PK)• What the body does to the drug
– Absorption, Distribution, Metabolism, Excretion
• Describes time course of drug in the body
Cmax
Pharmacodynamics (PD)
• What the drug does to the body (or the bug)
• Describes the relationship between drug exposure and effect
Cmax
PD and dose optimization
The parameter AUC/MIC correlates best with the bactericidal activity of RIF in the mouse model
Jayaram et al, AAC (2003)
W.A. Craig, Clin Infect Dis (1998)
9/28/2010
4
Population PK variability
McIlleron et al, AAC (2006)
One determinant of PK variability:Genetic differences in drug transporters
Weiner et al, AAC (2010)
“The probability that one and only one dose (e.g., rifampin 600 mg) is the correct dose for every human on the planet is approximatelyevery human on the planet is approximately
ZERO.”
C. Peloquin, Pharm.D.
9/28/2010
5
Rifampin is typically used at or near its minimally effective dose
• Early bactericidal activity1
RIF dose n EBA0-2
300 mg 3 0.06600 mg 8 0 19
• In DAILY combination therapy with INH2
– Pts receiving <9 mg/kg RIF more likely to have positive sputum cultures at 8, 16 and 20 wks
– 19% of pts administered 600 mg received <9 mg/kg
600 mg 8 0.19
1200 mg 8 0.41p<0.05
1Jindani et al, ARRD 1980; 121:9392Long et al, ARRD 1979; 119:879
Factors associated with reduced RIF exposure
• Population pharmacokineticsMarked differences person-to-person and dose-
to-dose differences in bioavailability1,2
• Patient-specific conditionsLarge body mass3,4 Hx of GI surgery3
Diabetes mellitus3,4 Poor nutritional status3
HIV infection2,3 Childhood5
1Antimicrob Agents Chemother (2008);52:2138 4Clin Infect Dis (2006);43:848 2Antimicrob Agents Chemother (2008);52:2138 5Clin Pharmacokinetics (1978);3:1083Drugs (2002);62:2169
Inferiority of intermittent regimens
Systematic review of published clinical trials with short-course regimens
Frequency of Initial Freq. of Continuation Odds of Relapse vs. q yPhase Therapy
qPhase Therapy
pDaily Therapy
Daily Daily 1.0Daily 3x/wk 1.6 (0.6 - 4.1)Daily 2x/wk 2.8 (1.3 - 6.1)3x/wk 3x/wk 2.8 (1.4 - 5.7)
Chang et al, AJRCCM (2006); 174:1153
9/28/2010
6
Low drug exposures are linked to emergence of resistance
• Among HIV+ pts receiving twice-weekly RBT-based Rx:– Failure/relapse in 5 3%– Failure/relapse in 5.3%– 8 of 9 with acquired
rifamycin resistance (ARR)
• Low RBT and INH exposures were associated with ARR
Weiner et al, Clin Infect Dis (2005)
Pharmacodynamics of daily rifapentine and rifampin in mice
15
cin /M
IC
15
cin /M
IC
Rifapentine (10mg/kg) Rifampin (10mg/kg)AUC/MIC = 899 μg-h/mL AUC/MIC = 311 μg-h/mL
0 24 48 72 96 120 144 1680
5
10
Time (hrs)
Free
rifa
myc
Con
cent
ratio
n/
0 24 48 72 96 120 144 1680
5
10
Time (hrs)
Free
rifa
myc
Con
cent
ratio
n/
Interim summary
• Low rifamycin and INH exposures have been associated with adverse outcomes
• Esp. for rifamycins, peculiarities in dosing and variable absorption results in sub-therapeutic p pexposures for some pts, sub-optimal exposures for most pts
• Optimizing rifamycin exposures, whether with rifapentine or rifampin, may result in shorter, more effective regimens for TB
9/28/2010
7
babi
lity
(%)
Toxicity
50
100Response
Prob
Drug Concentration (µg/ml)
10 20 30 40
Evans, 1986
AUC/MIC is the PD driver for the bactericidal effects of PZA in mice
T>MIC Cmax/MIC
AUC/MIC
Divorcing efficacy from toxicity
• In vitro & mouse studies show AUC/MIC predicts PZA’s bactericidal effects1,2
• Re-analysis of clinical data reveals that hyperuricemia is correlated with the duration of yptime that serum pyrazinamide concentrations exceed a toxic threshold3
• Therefore, dosing PZA intermittently (with proper dose multiplication) may alleviate arthralgias without sacrificing efficacy
1Gumbo et al, AAC (2009) 2Ahmad et al, ICAAC (2010) 3Pasipanodya et al, AAC (2010)
9/28/2010
8
Therapeutic drug monitoring
• May help determine the “right” dose for the patient in front of you
• Routine TDM may be cheaper than re-treatment in selected groupstreatment in selected groups
• Still, there are no prospective studies addressing whether routine TDM would improve outcomes
Cautionary tales
• In a cross-over PK study among HIV-TB pts1:– Reducing the thrice weekly dose of RBT from 300
to 150 mg maintained similar drug levels upon addition of LPVr
– But, 9 (90%) of 10 pts had low RBT conc. – 1 (10%) of 10 developed ARR
• Using routine TDM in pts with advanced HIV2:– 18 (86%) of 21 pts had rifamycin conc. below the
recommended minimum values
1 Boulanger et al, CID (2009) 2 Holland, Pharmacotherapy (2009)
Patients for whom TDM may be considered
• Advanced HIV disease– esp. if receiving RBT and ART
• GI co morbidity with risk of malabsorption• GI co-morbidity with risk of malabsorption• Severely ill • Obesity• Slow response to therapy (+ cx at 3 mo.?)
9/28/2010
9
4
5
6
Patterns of Absorption with Oral Drugs
0
1
2
3
0 1 2 3 4 5 6 7 8time (h)
Delayed
Malabsorpt
Normal
“Targets” for first-line drugs
• Isoniazid (300 mg) ≥ 3 µg/ml(900 mg) ≥ 9 µg/ml
• Rifampin ≥ 8 µg/mlRif b ti 0 3 / l• Rifabutin ≥ 0.3 µg/ml
• Pyrazinamide (25 mg/kg) ≥ 35 µg/ml• (50 mg/kg) ≥ 70 µg/ml
Peloquin, Drugs (2002) Chideya et al, CID (2008) Boulanger et al, CID (2009)
Depending on the clinical scenario, higher minimum concentrations may be warranted
Take-home points
1. The effect of TB drugs is proportional to the exposure achieved at the infection site
2. A single dose size does not fit all TB pts3 Adverse treatment outcomes are3. Adverse treatment outcomes are
associated with low drug exposures4. TDM should be considered for some pts
to ensure adequate drug exposure5. More data relating PK/PD of TB drugs to
clinical outcomes are needed
9/28/2010
10
Risk factors for Relapse in USPHS Study 22
21 8% 6.2%
Cavity?
Yes
Culture (+) at 2 months?Yes No
21.8%
2.1%5.0%No
Lancet, 2002
Lower rifabutin AUC linked with ARR versus cure
P-Value
*
AUC0-24
Med (IQC)
Dose mg/kgMed (IQC)
No.
Group
* P for RBT AUC ARR vs. cure, Mann-Whitney
0.045.1(4.0 - 7.4)
4.8(4.2 – 6.2)
82CURE
3.1(2.0 - 3.8)
4.6(3.5 - 5.7)
6ARR(IQC)
9/28/2010
11
TDM with Oral TB Drugs
Two hour post dose blood draws generallycapture the “peak” concentration.
Six hour post dose blood draws generallyseparate delayed absorption from malabsorption.p y p p
Peloquin CA. Therapeutic Drug Monitoring in the Treatment of Tuberculosis. Drugs 2002; 62: 2169 -2183.
Clinical trials planned or underwayPhase III study of intermittent P- and M-containing continuation phase regimensSponsor (PI) Location(s) Test regimens Primary outcomes
St. George’s U. (A. Jindani)
S. Africa 2RMZE + 4P20M (1/7)2RMZE + 2P15M (2/7)
RelapseRifamycin resistance
Phase II studies of daily P- +/- M-containing initial phase regimensPhase II studies of daily P / M containing initial phase regimensSponsor (PI) Location(s) Test regimens Primary endpointsCDC TBTC(S. Dorman)
29 sites in NAm, Africa, Brazil, Spain
2P10HZE Sputum Cx conversionTolerability
JHU(S. Dorman)
South Africa 2P7.5HZE2P10HZE
Sputum Cx conversionTolerability
JHU(S. Dorman)
Brazil 2P10HZM Sputum Cx conversionTolerability
Q. How high of a dose can you give?A.As high as necessary
Actual examples :
INH 900 d il RIF 2100 d il
TDM
INH 900 mg daily, RIF 2100 mg dailybecause most of the doses were ending upin the patient’s stool.
Otherwise, if you keep doing what you have been doing, you will keep getting what you have been getting.
9/28/2010
12
Clinical courseRapid tests: smear-positive w/ heavy AFB, MTD positive
HIV-negative
Treatment: INH 300mg, RIF 600mg, PZA 2g, EMB 2g (5/7) x 3w,began INH 900mg, RIF 600mg, PZA 4g, EMB 4g (2/7) x 6w,9/15 INH 900mg, RIF 600mg (2/7)
Sputum culture: positive for M. tuberculosis, pan-susceptible
Response: 1/11: still symptomatic, slight improvement in CXR smear-neg., culture-pos. w/ pan-susceptible Mtb
Intervention: 2/1: Dosing frequency increased to (3/7)2/23: Drug levels: INH 8.84 μg/ml (goal = 9 -15)
RIF 5.85 μg/ml (goal = 8 -24)3/7: restarted 4-drug Rx w/ INH 400mg, RIF 900mg;
completed 6 mo. of daily therapy at these doses
45678
R10HZR15HZR20HZR40HZ
U p
er L
ung
Bactericidal effect of escalating RIF doses
0 2 4 6 8 10 1201234
P10HZ
Treatment duration (weeks)
Log 1
0 C
FU
Pharmacodynamics of INH activity
0
0.2
0.4
0.6
0.8
1
0 2 0 5 0 8 1 1 1 4 1 7
Log
kill
afte
r 5 d
oses
Mouse
-0.20.2 0.5 0.8 1.1 1.4 1.7
Log dose of isoniazid (mg/kg)
Jayaram et al, AAC 2004
Donald et al, AJRCCM 1997
Human
9/28/2010
13
Conclusions II
• Both rifamycins display dose-dependent sterilizing activity in mice
• The best rifamycin for daily therapy is the y y pyone best tolerated at highest exposure level
Objectives of talk
1. Review the role of the rifamycins in TB therapy 2. Briefly discuss factors associated with sub-
therapeutic rifampin exposure3 Posit that rifampin exposure is sub optimal in3. Posit that rifampin exposure is sub-optimal in
most patients with TB4. Convince you that optimizing rifamycin
exposures could significantly shorten the duration of treatment for TB
Rifampin
9/28/2010
14
Effect of dose and frequency on RIF activity in chronic mouse infection
Lung CFU counts after 6 wks treatment with rifampin at the indicated dose (mg/kg)
5
6
nt
Initial CFU ct
0
1
2
3
4
(2/7) (3/7) (6/7)
Frequency of administration
Log(
10) l
ung
CFU
cou
n
510
Ji et al, ARRD 1993; 148:1541
Influenza-like syndrome associated with high-dose, intermittent RIF
Study Dose (mg) Frequency Incidence (%)BMRC Hong Kong trials1
1200 1/7 44900 1/7 36900 2/7 22450 5/7 0450 5/7 0
Grosset & Leventis2
1200-1800 1/7 35-371200-1800 2/7 16-22
900 1/7 22-31900 2/7 8600 1/7 10600 2/7 1-4
1Medicine (1999); 78:3612 Rev Infect Dis (1983); 5 Suppl 3:S440
Rifapentine (RPT, P)
• MIC90 = 0.06 μg/ml (vs. 0.25 for RIF)
• Half-life = 14-18 h (vs. 2-4 for RIF)
• Developed as a rifamycin for once-weekly regimens
• Approved for this purpose in 1998
9/28/2010
15
Clinical trials of once-weekly rifapentine-containing regimens
Variable
Hong Kong Chest Service
Trial
HMR Protocol 008 Trial
USPHS TB Trials Consortium Study
22
Intensive phase regimen
HRZS (3/7) HRZE (7/7) orHZE (7/7)+P (2/7)
HRZ(E/S) (7/7, 3/7 or 2/7)( ) ( )
Continuation phase regimen
HR (3/7) orHP (1/7)
HR (2/7) orHP (1/7)
HR (2/7) orHP (1/7)
Proportion (%) with relapse +/-treatment failure
7/190 (3.7%)17/199 (8.5%)
11/229 (5%)25/249 (10%)
22/246 (8.9%)a
40/278 (14.4%)a
6/241 (2.5%)b
6/210 (2.9%)b
awith cavitation on CXR bwithout cavitation on CXR
Adapted from Munsiff et al, Clin Infect Dis (2006); 43:1468
Restrictions on use of rifapentine
“(once-weekly HP) should be used only in HIV-negative pts without cavitation who have
negative sputum smears at 2 mo.”
“For pts with a positive culture at 2 mo., treatment should be extended an extra 3 mo.”
Paraphrased from ATS/CDC/IDSA guidelines, Am J Respir Crit Care Med (2003); 167:603
The potential for increasing rifapentine exposures
• Some patients in HMR study accidentally received RPT 600 mg daily in initial phase
O h i l d 600 d il f• Other patients tolerated 600 mg daily for over 1 week in a PK study1
• Dose-dependent activity in mouse and in humans over a 600-1200 mg range that is well tolerated when given once weekly2-4
2Daniel et al, AJRCCM 2000; 161:15724Bock et al, AJRCCM 2002; 165:1526
1Keung et al, IJTLD 1999; 3:4373Sirgel et al, AJRCCM 2005;172:128
9/28/2010
16
Twice-weekly, High-dose RPT in the Mouse Lung CFU counts after 2 Months Treatment
3
4
2.56
3.61
2.88 3.06
1 68
2.37
FU c
ount
RHZ (5/7)
RHZ (2/7)
RMZ (2/7)
HZ (2/7)
10PHZ (2
/7)
15PHZ (2
/7)
20PMZ (2
/7)
15PMZ (2
/7)
20P
0
1
2
0.842
0.350
1.68
Lung
log
CF
Rosenthal et al, AJRCCM 2006
Twice-weekly, High-dose RPT in the Mouse Lung CFU counts after 2 Months Treatment
3
4
2.56
3.61
2.88 3.06
1 68
2.37
FU c
ount
RHZ (5/7)
RHZ (2/7)
RMZ (2/7)
HZ (2/7)
10PHZ (2
/7)
15PHZ (2
/7)
20PMZ (2
/7)
15PMZ (2
/7)
20P
0
1
2
0.842
0.350
1.68
Lung
log
CF
Rosenthal et al, AJRCCM 2006
Time to Culture Negativity with More Frequent Administration of RPT
5678
2R10HZ + 4R10H (5/7)2P20MZ (2/7)2P15MZ (3/7)2P10MZ (5/7)co
unt i
ns
Cx-: Culture negative, *: 1/5 mice culture positive with 1 CFU/Lung
0 1 2 3 4 5 601234
Cx-
2P10MZ (5/7)
*
Duration of Treatment (mos.)
Log 1
0 C
FU c
lung
9/28/2010
17
Relapse rates after more frequent dosing of PMZ regimens
RegimenAfter 2
mo.After 3
mo.After 4
mo.After 6
mo.
RHZ (5/7) Cx+ Cx+ 90% 0%
P15MZ (3/7) 95% 0% _ _
P10MZ (5/7) 35% 0% _ _
(Cx+) All mice tested at treatment completion were culture positive
Can the same benefit be accomplished with rifampin?p p
Relapse after 8, 10 & 12 wks treatment
Regimen(with HZ)
Proportion (%) of mice relapsing after Rx for:8 wks 10 wks 12 wks
R20 ND 100% (15/15) 67% (10/15)P5 ND 100% (15/15) 67% (10/15)R40 ND 27% (4/15) 0% (0/15)P10 100% (15/15) 33% (5/15) 0% (0/15)
9/28/2010
18
Recapitulation of the short-course regimen in the mouse…as in humans?
5
6
7
8
INH + SMINH + RIFINH + RIF + PZAn
lung
s
0
1
2
3
4
0 2 4 6 12 18
INH + RPT + PZA
months
Log 1
0cf
u i
Tubercle 1978: 59:287 & 1986;67:5
AcknowledgementsMentors
Jacques Grosset Bill Bishai
TB Murine Trials ConsortiumIan Rosenthal Ming ZhangSandeep Tyagi Kathy WilliamsTianyu Zhang Si-Yang Li
CollaboratorsDick Chaisson Susan DormanAndrew Vernon Charles Peloquin
Funding Agencies:NIH/NIAID Potts Memorial Foundation
9/28/2010
19
Objectives of TB Therapy• Kill actively multiplying bacteria
– Improve symptoms & prevent death– Prevent transmission to others
Prevent emergence of resistance– Prevent emergence of resistance
• Sterilize disease sites– Cure the disease
Bacterial Targets of TB Therapy
• Rapidly multiplying bacteria (in cavities)
• Slowly multiplying bacteria (in acidic y p y g (environment of macrophages or cavity wall)
• Sporadically multiplying bacteria (location?)
A
Hypothetical Model of TB Chemotherapy3 anatomic/metabolic populations of bacilli in cavitary TB
A: rapidly multiplying, INH>RIF>EMBB: slowly multiplying, acid pH, PZA>RIF>INHC: sporadically multiplying, RIF>INH
M. Iseman, D. Mitchison
B
C
# ba
cilli
# months of therapy1 2 3 4 5 6
9/28/2010
20
Isoniazid (INH)
DosagePO or IV/IM
Metabolism Side Effects Drug-Drug Interactions
5 mg/kg qd (300 mg qd)
Liver Hepatitis Phenytoin(300 mg qd)
15 mg/kg b.i.w. (900 mg)
15 mg/kg t.i.w. (900 mg)
Food, aluminum-containing antacids reduce absorption
NeuropathyLupus
(pyridoxine decreases risk of
neuropathy*)
Carbamazepine
Disulfuram
*use pyridoxine 25-50 mg for HIV, pregnancy, malnourished, EtOHism, diabetes, liver dz, cancer
Rifampin (RIF)
Dosage*PO or IV/IM
Metabolism Side Effects Drug-Drug Interactions
10 mg/kg Liver N/V Multiple:g g
(600 mg q.d.)(600 mg b.i.w)(600 mg t.i.w)
Food, antacids slow GI uptake
Hepatitis“Flu-like” sx↓Platelets
Orange staining of secretions
pOCPs
MethadoneHIV drugsCoumadin
*RPT dose 600-900 mg q weekRBT dose 300 mg QD
Pyrazinamide (PZA)
DosagePO
Metabolism Side Effects
15-30 mg/kg qd Liver Hepatitis(2 gm)
50-70 mg/kg b.i.w. (4 gm)
50-70 mg/kg t.i.w (3 gm)
Metabolites excreted by
kidney
Joint painGoutRash
Nausea
9/28/2010
21
Cmax
AUC / MIC
10
8
Cmax = 9 mcg / ml
MIC = 3 mcg / ml
Cmax / MIC = 3
PD: Response Parameters
MIC
AUC / MIC6
4
2
0
T > MIC = 8 h
AUC ( mcg * h / ml )
Concentration-dependent killers• Activity correlated with Cmax/MIC• Examples: aminoglycosides, FQsTime-dependent killers• Activity correlated with T>MIC• Examples: β-lactams
An example of dose fractionation
A total dose of 300 mg/kg may be divided over 6 days as follows:– 300 mg/kg every 6 days
150 mg/kg every 3 days g– 150 mg/kg every 3 days– 100 mg/kg every other day– 50 mg/kg every day– 25 mg/kg every 12 hours In
crea
sing
C
max
/MIC
Incr
easi
n gT
>MIC
Example of a dose fractionation study
The parameter AUC/MIC correlates best with the bactericidal activity of RIF in the mouse model
Jayaram et al, AAC 2003; 47:2118
9/28/2010
22
Top Related